Quick Answer
Bioventus Inc. reported R&D Expense of $12.11 million for fiscal year 2025.
Bioventus Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $12.11M | -13.2% |
| 2024 | $13.95M | +3.8% |
| 2023 | $13.45M | -43.6% |
| 2022 | $23.85M | +25.3% |
| 2021 | $19.04M | +70.0% |
| 2020 | $11.20M | +1.3% |
| 2019 | $11.05M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.92M | -23.9% | -7.8% |
| June 30, 2025 | $3.17M | -24.7% | +5.3% |
| March 31, 2025 | $3.01M | +14.6% | -21.6% |
| September 30, 2024 | $3.84M | +27.5% | -8.7% |
| June 30, 2024 | $4.21M | +23.9% | +60.3% |
| March 31, 2024 | $2.63M | -30.3% | -12.9% |
| September 30, 2023 | $3.02M | -34.7% | -11.3% |
| June 30, 2023 | $3.40M | -46.6% | -9.9% |
- Bioventus Inc. showed a decrease of -13.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Bioventus Inc.’s r&d expense has grown by 9.6% (from $11.05 million to $12.11 million).
- The most recent figure is from Bioventus Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: